• A Disease Registry for Patients with Chronic Lymphocytic Leukemia (CLL)

    To describe current treatment patterns in the real-world setting among CLL patients who are initiating treatment with novel therapies including approved oral kinase inhibitors, BCL2 inhibitors, or other approved anti-CLL therapies/regimens as first- or later-line therapy, & explore the associations with baseline patient characteristics, healthcare resource utilization, & clinical outcomes.